Skip to main content
Richard Riedel, MD, Oncology, Durham, NC, Duke University Hospital

RichardFrancisRiedelMD

Oncology Durham, NC

Associate Professor, Division of Medical Oncology, Department of Medicine, Duke University Medical Center

Dr. Riedel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Riedel's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology and Medical Oncology, 2003 - 2007
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2000 - 2003
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2000

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 2000 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Experiences of Older Caregivers of Cancer Patients Following Hospital Discharge  
    Richard F Riedel, Ellen Mahoney, Thomas W LeBlanc, Cristina C Hendrix, Supportive care in cancer

Lectures

  • A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SAR... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
  • Is There an Optimal Treatment Sequence for Systemic Therapy in Metastatic Disease? 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018

Press Mentions

  • Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas
    Bad to the Bone: Emerging Approaches to Aggressive Bone SarcomasMay 1st, 2023
  • Thumbs up from FDA Panel for Sarcoma Drug
    Thumbs up from FDA Panel for Sarcoma DrugDecember 18th, 2019
  • Epizyme’s Sarcoma Drug Sails Through FDA Panel with Unanimous Vote
    Epizyme’s Sarcoma Drug Sails Through FDA Panel with Unanimous VoteDecember 18th, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations